研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

上皮样血管内皮瘤是一种危险、容易被忽视且几乎不可能临床诊断的疾病:病例报告。

Epithelioid Hemangioendothelioma as a Dangerous, Easy to Miss, and Nearly Impossible to Clinically Diagnose Condition: Case Report.

发表日期:2024 Aug 28
作者: Kayd Pulsipher, Samantha Mills, Blair Harris, Rene Bermudez, Muammar Arida, Jonathan Crane
来源: Cellular & Molecular Immunology

摘要:

上皮样血管内皮瘤(EHE)是一种罕见的具有转移潜力的血管肿瘤。 EHE 可累及单个或多器官,其表现范围从无症状疾病到疼痛和全身症状。极其异质的临床表现和疾病进展使 EHE 的诊断和管理变得复杂。我们介绍了一名 24 岁女性的病例,她患有两处耳周红斑丘疹,尽管没有相关病史,但通过常规活检发现了转移性 EHE。组织学显示真皮样上皮细胞和含有红细胞的空泡增殖。与 EHE 一致的免疫组织化学标记物巩固了诊断。尽管 EHE 极为罕见,但及时诊断对于做出明智的决策和获得良好的结果至关重要。重点介绍了关键的临床和组织病理学发现,以帮助皮肤科医生诊断和治疗这种罕见疾病。©Kayd Pulsipher、Samantha Mills、Blair Harris、Rene Bermudez、Muammar Arida、Jonathan Crane。最初发表于 JMIR Dermatology (http://derma.jmir.org),2024 年 8 月 28 日。
Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor with metastatic potential. EHE can have single- or multiorgan involvement, with presentations ranging from asymptomatic disease to pain and systemic symptoms. The extremely heterogeneous clinical presentation and disease progression complicates EHE diagnosis and management. We present the case of a 24-year-old woman with two periauricular erythematous papules, leading to the discovery of metastatic EHE through routine biopsy, despite a noncontributory medical history. Histology revealed the dermal proliferation of epithelioid cells and vacuoles containing red blood cells. Immunohistochemistry markers consistent with EHE solidified the diagnosis. Although extremely rare, prompt diagnosis of EHE is essential for informed decision-making and favorable outcomes. Key clinical and histopathological findings are highlighted to aid dermatologists in diagnosing and managing this uncommon condition.©Kayd Pulsipher, Samantha Mills, Blair Harris, Rene Bermudez, Muammar Arida, Jonathan Crane. Originally published in JMIR Dermatology (http://derma.jmir.org), 28.08.2024.